A Clearer Path in Brain Surgery: SonoClear Nears US Market

OSLO, Norway – May 12, 2026 – Norwegian medical technology firm SonoClear AS announced today it has completed clinical trial enrollment for its innovative SonoClear® System, a device poised to solve a critical imaging challenge in neurosurgery. The milestone moves the company significantly closer to seeking U.S. market clearance for a technology designed to give surgeons a crystal-clear view when removing brain tumors.

Having received a coveted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) in 2025, SonoClear is now analyzing the final data from its multicenter study. The company intends to submit a 510(k) application to the FDA in the second half of 2026, a pivotal step in bringing its solution to operating rooms and patients.

"Having achieved this critical milestone, we are now completing our data analysis and preparing to submit for marketing clearance in the United States," said Peter Balmforth, CEO of SonoClear. "We are grateful to the patients, investigators, and clinical teams who have contributed to the study."

The Challenge of the Last Millimeter

For neurosurgeons, the success of a brain tumor operation often hinges on a principle of maximal safe resection—removing as much of the cancerous tissue as possible without damaging healthy brain function. The amount of residual tumor left behind is a primary driver of patient survival and recurrence rates, particularly with aggressive cancers like glioblastoma. Studies have shown that even small amounts of remaining tumor can negatively impact patient outcomes and may even accelerate regrowth.

To guide their work in real-time, surgeons frequently rely on intraoperative ultrasound (IOUS). Unlike pre-operative MRIs, IOUS can account for "brain shift," the subtle changes in the brain's position that occur once surgery begins. However, standard IOUS has a significant Achilles' heel: acoustic artifacts. When a surgeon creates a cavity by removing tumor tissue, it is typically filled with a standard irrigation fluid like saline. Because saline has vastly different acoustic properties than brain tissue, the ultrasound waves passing through it create bright, noisy signals known as acoustic enhancement artifacts. These artifacts can obscure the base of the surgical cavity, precisely where distinguishing between the last remnants of a tumor and healthy tissue is most critical.

This visual noise forces surgeons to contend with a compromised view at the most crucial stage of the procedure, making the goal of total resection a formidable challenge. The inability to clearly see and remove the final millimeter of a tumor can be the difference between a successful long-term outcome and a rapid recurrence of the disease.

A Clearer View: Sharpening Surgical Vision

The SonoClear System was engineered to directly address this fundamental problem. It is not a new imaging machine but rather a sterile, biocompatible acoustic coupling fluid designed to replace conventional saline during IOUS procedures. The key innovation lies in its composition; the fluid is specifically formulated to match the acoustic properties of brain tissue.

By filling the resection cavity with the SonoClear fluid, the acoustic mismatch that causes disruptive artifacts is eliminated. This provides surgeons with a clean, unobstructed ultrasound image, allowing for a detailed inspection of the surgical margins. The company's Chief Medical Officer, Prof. Geirmund Unsgård, explained the core concept: "With conventional irrigation fluids there are acoustic artifacts that obscure critical tumor remnants at the base of a resection cavity that make maximum tumor resection challenging. SonoClear System's tissue-mimicking properties were designed to address this issue."

Early experiences from clinical investigators in the now-completed study have been promising. Prof. Dr. Constantin Roder, a neurosurgeon at Universitätsklinikum Tübingen who participated in the trial, noted the system's practical benefits. "When using the SonoClear System in multiple neurosurgical cases, the kit fit well into our normal operating room workflow," he stated. "If our experience with SonoClear is reflected in the overall study results, then SonoClear could meaningfully enhance the image quality of intraoperative ultrasound at the end of resection."

Navigating the Path to Market

The FDA's decision to grant the SonoClear System Breakthrough Device designation in July 2025 underscores the technology's potential to address a significant unmet need. This program is designed to expedite the development and review of devices that offer more effective treatment for life-threatening or debilitating conditions. It provides SonoClear with a more collaborative and prioritized review process with the FDA, potentially shortening the timeline to market availability.

Completing the clinical enrollment is the most recent success in this accelerated pathway. "Importantly, this study evaluates the safety of the SonoClear System in routine intraoperative ultrasound use and compares its performance with standard irrigation fluids," commented Prof. Dr. med. Jan Coburger of Ulm University Hospital, the study's primary investigator. "Completing enrollment is an important step toward understanding the system's potential value across a broader clinical experience."

By enhancing the performance of existing and widely available IOUS equipment, SonoClear offers a distinct advantage over other high-tech solutions like intraoperative MRI (iMRI). While iMRI provides excellent image quality, it requires massive capital investment and specialized operating suites, limiting its adoption to major medical centers. SonoClear's approach is to upgrade, rather than replace, existing infrastructure, making its potential benefits accessible to a much broader range of hospitals and patients.

From Norwegian Lab to Global Impact

SonoClear AS represents a modern success story in medical innovation, having been spun out of the prestigious Ultrasound and Image-Guided Therapy Centre in Trondheim, Norway. This origin reflects a deep foundation in scientific research, focused on translating laboratory discoveries into practical clinical tools. The company's mission is to improve diagnostic accuracy in ultrasound-guided interventions, and its neurosurgical system is its flagship product.

The company is backed by a strong consortium of investors, including SINTEF Venture IV (the venture arm of one of Europe's largest research organizations), Sarsia, CoFounder, and Sparebank 1 SMN. This blend of research-affiliated, venture capital, and regional financial support provides a stable platform for growth as the company prepares for its U.S. market entry.

With clinical enrollment complete, the focus now shifts to rigorous data analysis. The forthcoming results will be critical for the company's FDA submission and will ultimately determine if this innovative Norwegian technology can become a new standard of care, offering a brighter future for brain tumor patients by giving surgeons the clear view they have long needed.